VeriSIM Life, Total Brain to develop drugs for broad range of neurological disorders

VeriSIM Life announced it will partner with neuroscience firm Total Brain to develop new drugs for the treatment of a wide range of neurological disorders, the company announced through a press release.

According to the release, the collaboration will integrate Total Brain’s proprietary mental health and brain performance database with VeriSIM Life’s BIOiSIM artificial intelligence-enabled drug development decision engine to facilitate new psychiatric and neurological therapies.

“We are excited to partner with Total Brain to combine the power of their high-dimensional data with our drug prediction engine to open new doors for drug discovery specifically addressing neurological conditions — something that has never been explored this way before,” Jo Varshney, PhD, founder and CEO of VeriSIM Life, said in the release.

With this partnership, BIOiSIM will use its translational index to discover novel drug candidates with other capabilities such as evaluating safety and efficacy of existing drugs and drug candidates used to treat neurological conditions in specific patient subpopulations, assisting biotechnology companies in developing genetics prediction products and developing companion diagnostics tracking essential biomarker data during drug development.

“The collaboration between Total Brain and VeriSIM has the potential to accelerate the pace of drug development, reduce costs and minimize failed drug discovery for neurological diseases,” Evian Gordon, MD, PhD, chief medical officer at Total Brain, said in the release.